1. Introduction
===============

*Sanguisorba officinalis* L. (Rosaceae) is a perennial plant widely distributed in China, and its roots have been used as a traditional Chinese medicine for the treatment of hemostasis and inflammation \[[@B1-molecules-17-07629]\]. A variety of chemical constituents, including tannins, triterpenoids, flavonoids, anthraquinones, steroids were isolated from *S. officinalis* L., and pharmacological studies on its hemostatic and anti-inflammatory properties have been reported \[[@B2-molecules-17-07629],[@B3-molecules-17-07629]\], but the molecular level mechanisms of these activities have not been reported until now. In order to study the mechanism of hemostasis, we have carried out the bioassay-guided isolation and identification of hemostatic constituents of the roots of *S. officinalis* L. In the present study, we report the isolation and identification of a new monoterpene glycoside **1**, together with two known monoterpene glycosides **2**, **3** and four known triterpenoids **4**--**7**, and their hemostatic activities.

2. Results and Discussion
=========================

Compound **1**, a colorless amorphous powder, produced a positive reaction to Molish reagent, and had the molecular formula C~21~H~38~O~10~ as determined by HRESIMS (\[M+Na\]^+^ *m/z*473.2369). Its IR spectrum indicated the presence of hydroxyl (3450 cm^−1^) groups. Acid hydrolysis of compound **1** gave [D]{.smallcaps}-glucose and [L]{.smallcaps}-arabinose. The ^1^H-, ^13^C- and DEPT-NMR spectrum (DMSO-d~6~) of compound **1** showed signals of a monoterpene moiety consisting of two singlets and one double methyl groups \[δ~H~ 1.64 (3H, s, H-8), 1.56 (3H, s, H-9), and 0.85 (3H, d, *J* = 6.4 Hz H-10); δ~C~ 25.5 (C-8), 17.5 (C-9), and 19.3 (C-10)\], four methylenes \[δ~H~ 3.41 and 3.76 (each 1H, m, H-1), 1.32 and 1.56 (each 1H, m, H-2), 1.12 and 1.29 (each 1H, m, H-4), and 1.93 (2H, m, H-5); δ~C~ 66.9 (C-1), 36.3 (C-2), 36.8 (C-4), and 24.9 (C-5)\], one olefinic methine \[δ~H~ 1.52 (1H, m, H-3); δ~C~ 28.9 (C-3)\], and one carbon-carbon double bond \[δ~H~ 5.09 (1H, t-like, *J* = 7.2 Hz, H-6); δ~C~ 124.7 (C-6) and 130.4 (C-4)\]. Based on the 2D NMR data of H-H COSY, HMQC and HMBC experiments, the monoterpene moiety was identified as citronellol \[[@B4-molecules-17-07629]\]. The coupling constant of the anomeric proton of glucose at δ 4.11 (d, 1H, *J* = 8.0 Hz) indicated that glucose moiety was in a β-configuration. The HMBC correlation signal of the anomeric proton of glucose, 1\'-H (δ~H~ 4.11) to C-1 (δ~C~ 66.9) showed that glucose was linked to C-1 of the alycone. The downfield shift by about 5 ppm of the signal of C-6\' of glucose (δ~C~ 67.2) showed that arabinose was linked to C-6\' of the glucose, which was further confirmed by the HMBC correlations of 6\'-H (δ~H~ 3.39 and 3.85) to C-1\" (δ~C~ 108.5) of arabinose and 1\"-H (δ~H~ 4.79) to C-6\' (δ~C~ 67.2). The ^13^C-NMR signals of compound **1** assignable to the arabinose moiety \[δ~C~ 82.0 (C-2\"), 83.8 (C-2\")\] and the coupling constant of the anomeric proton of arabinose at δ~H~ 4.79 (d, 1H, *J* = 1.6 Hz) indicated that arabinose moiety was an α- [L]{.smallcaps} -arabinofuranose moiety \[[@B5-molecules-17-07629]\], which was further confirmed by the HMBC correlation of 1\"-H (δ~H~ 4.79) to C-4\" (δ~C~ 83.8). The complete assignment of the signals of compound **1** was based on DEPT ^13^C-NMR and 2D-NMR H-H COSY, HMQC and HMBC data. For all the ^1^H-, ^13^C-, and HMBC NMR data of compound **1** see [Table 1](#molecules-17-07629-t001){ref-type="table"}, and for the structure of compound **1**, see [Figure 1](#molecules-17-07629-f001){ref-type="fig"}. Therefore, the structure of compound **1** was elucidated as citronellol-1-O-α-[L]{.smallcaps}-arabinofuranosyl-(1→6)-α-[D]{.smallcaps}-glucopyranoside.

Using similar methods as described above, compounds **2**--**7** were identified as geraniol-1-*O*-α-[L]{.smallcaps}-arabinofuranosyl-(1→6)-β-[D]{.smallcaps}-glucopyranoside (**2**) \[[@B5-molecules-17-07629]\], geraniol-1-*O*-α-[L]{.smallcaps}-arabinopyranosyl-(1→6)-β-[D]{.smallcaps}-glucopyranoside (**3**) \[[@B5-molecules-17-07629]\], 3β-\[(α-[L]{.smallcaps}-arabinopyranosyl)oxy\]-19α-hydroxyolean-12-en-28-oic acid 28-β-[D]{.smallcaps}-glucopyranoside (**4**) \[[@B6-molecules-17-07629]\], 3β-\[(α-[L]{.smallcaps}-arabinopyranosyl)oxy\]-19α-hydroxyurs-12-en-28-oic acid 28-β-[D]{.smallcaps}-glucopyranoside (ziyu-glycoside І, **5**) \[[@B7-molecules-17-07629]\], 3β,19α-hydroxyolean-12-en-28-oic acid 28-β-[D]{.smallcaps}-gluco-pyranoside (**6**) \[[@B8-molecules-17-07629]\], 3β,19α-dihydroxyurs-12-en-28-oic acid 28-β-[D]{.smallcaps}-glucopyranoside (**7**) \[[@B8-molecules-17-07629]\], respectively.

molecules-17-07629-t001_Table 1

###### 

^1^H-NMR (400 MHz), ^13^C-NMR (100 MHz), HMQC and HMBC data of compound **1** (DMSO-d~6~, δppm).

  No.   δC      δH                                HMBC(H→C)           No.      δC      δH                                                                   HMBC(H→C)
  ----- ------- --------------------------------- ------------------- -------- ------- -------------------------------------------------------------------- ------------------
  1     66.9    3.41, 3.76 (m, each 1H)           28.9, 102.8         1\'      102.8   4.11 (d, 1H, *J* = 8.0 Hz)                                           66.9, 75.4, 76.7
  2     36.3    1.32, 1.56 (m, each 1H)           19.3, 36.8,         2\'      73.4    2.93 (t-like, 1H, *J* = 8.0 Hz)                                      
  3     28.9    1.52 (m, 1H)                      66.9                3\'      76.7    3.13 (t, 1H, *J* = 8.8 Hz)                                           
  4     36.8    1.12, 1.29 (m, each 1H)           19.3, 36.3, 124.7   4\'      70.4    2.98 (t-like, 1H, *J* = 8.4 Hz)                                      73.4
  5     24.9    1.93 (m, 2H)                      28.9, 130.4         5\'      75.4    3.28 (t-like, 1H, *J* = 8.4 Hz)                                      102.8
  6     124.7   5.09 (t-like, 1H, *J* = 7.2 Hz)   17.5, 25.5, 36.8    6\'      67.2    3.85 (d-like, 1H, *J* = 10.8 Hz), 3.39 (dd, 1H, *J*= 10.8, 8.4 Hz)   108.5
  7     130.4                                                         ara(f)                                                                                
  8     25.5    1.64 (s, 3H)                      17.5, 124.7         1\"      108.5   4.79 (d, 1H, *J* = 1.6 Hz)                                           67.2, 77.2, 83.8
  9     17.5    1.56 (s, 3H)                      25.5, 124.7         2\"      82.0    3.79 (m, 1H)                                                         
  10    19.3    0.85 (d, 3H, *J* = 6.4 Hz)        36.3, 36.8          3\"      77.2    3.62 (m, 1H)                                                         
                                                                      4\"      83.8    3.72 (m, 1H)                                                         
                                                                      5\"      61.4    3.55 (dd, 1H, *J* = 11.6, 2.0 Hz), 3.40 (m, 1H)                      

All assignments based on extensive 1D and 2D NMR experiments (HMQC, HMBC, 1H-1H COSY).

![The key HMBC correlations of compound **1**.](molecules-17-07629-g001){#molecules-17-07629-f001}

Compounds **1**--**7** were next assayed for hemostatic activity with a Goat Anti-Human α2-plasmin inhibitor ELISA kit, and the results are shown in [Table 2](#molecules-17-07629-t002){ref-type="table"}. The data proved that ziyu-glycoside I showed strongest hemostasis activity within 7 kinds of terpene glycosides. It is the first report that ziyu-glycoside І (**5**) has strong hemostatic activity.

molecules-17-07629-t002_Table 2

###### 

The hemostasis assay data of the separated fractions and the isolated compounds.

  ------------------------ --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- ------------------- ----------------------
  **Fractions**            **H~2~O**       **30% EtOH**    **70% EtOH**    **95% EtOH**    **I**           **II**          **III**         **IV**          **Control blank**   **Standard**(10 g/L)
  **OD value**(n = 3)      0.056 ± 0.011   0.053 ± 0.002   0.131 ± 0.014   0.051 ± 0.006   0.051 ± 0.005   0.051 ± 0.006   0.490 ± 0.017   0.061 ± 0.004   0.028 ± 0.004       0.828 ± 0.031
  **Percent inhibition**   3.5             3.1             12.8            2.9             2.9             2.9             57.8            4.1                                 
  **Compounds**            **1**           **2**           **3**           **4**           **5**           **6**           **7**                           **Control blank**   **Standard**(10 g/L)
  **OD value** (n = 3)     0.138 ± 0.016   0.111 ± 0.009   0.122 ± 0.003   0.260 ± 0.013   0.741 ± 0.012   0.227 ± 0.010   0.214 ± 0.015                   0.060 ± 0.004       0.828 ± 0.031
  **Percent inhibition**   10.2            6.6             8.1             26.0            88.7            21.7            20.1                                                
  ------------------------ --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- ------------------- ----------------------

Note: Percent inhibition = \[(OD~sample~ − OD~blank~) ÷ (OD~standard~ − OD~blank~)\] × 100; the OD value is directly proportional the concentration of α2-plasmin inhibitor present in the samples.

3. Experimental
===============

3.1. General
------------

IR spectra were recorded on a FT-IR 5DX Nicolet/Nicolet Magna IR-560 spectrometer (Thermo Scientific, Osaka, Japan). ^1^H- and ^13^C-NMR spectra were recorded on a Bruker AV-400 spectrometer (Zürich, Switzerland). HR-ESI-MS were recorded on a Bruker microOTOF-Q II mass spectrometer. Prep. HPLC was performed on a Shimadzu LC-10A equipped with a SPD-10A detector and Gemini 5μm C18 110A column (250 mm × 10.00 mm, 5 μm, flow rate: 3.0 mL/min). The bioactivities were measured on a DG5033A Enzyme immunoassay spectrophotometer (Nanjing, China), using Goat Anti-Human α2-plasmin inhibitor ELISA kit \[96/48-wells microtiter plates, plastic cover, standard (40 g/L), blank control, standard diluent, biotinylated anti-α2-plasmin inhibitor, streptavidin-HRP, washing buffer, substrate A, substrate B, stopping solution, sample diluent)\] (R&D Systems, Minneapolis, MN, USA). The roots of *S. officinalis* L. were collected in Tong-Hua County in Jilin Province, China. They were identified by Prof. Jing-min Zhang of School of Pharmaceutical Sciences, Jilin University.

3.2. Extraction and Isolation
-----------------------------

The air-dried the roots of *S. officinalis* (4.0 kg) were extracted with hot 70% EtOH (ca. 20 L, 24 h, 45 °C). The EtOH extract was concentrated under reduced pressure, and the viscous concentrate (420 g) was passed through a D101 polyporous resin column eluting successively with H~2~O, 30% EtOH, 70% EtOH, and 95% EtOH, and by vacuum distillation recovery, four fractions (I--IV) were obtained. The bioassay experiments suggested that the 70% EtOH portion had hemostatic activity. Therefore the 70% EtOH fraction was subjected to silica gel column chromatography eluted with a stepwise gradient mixture of CHCl~3~--MeOH (9:1; 6:1; 3:1), and finally with MeOH alone, and four fractionons (I--IV) were obtained. Fraction III having hemostasis activity was further subjected to a silica gel column eluted with CHCl~3~--MeOH--EtOAc--H~2~O (6.5:5:4:1.7), and three fractions (A, B, C) were obtained. Fraction B was applied to a ODS-A (50 μm, 12 nm, YMC, Kyoto, Japan) column eluted with a stepwise gradient mixture of MeOH-H~2~O (2:3; 3:2; 4:1), and thus compound **5** (230 mg) and Fraction D were obtained. Fractions A, C, and D were separated by preparative HPLC using MeOH--H~2~O (60:40, 70:30, 65:35, respectively), and compound **1** (22 mg), **2** (25 mg), and **3** (27 mg) were isolated from fraction A, compound **6** (30 mg) and **7** (33 mg) from fraction C, and compound **4** (30 mg) from Fraction B.

Compound **1**: Colorless amorphous powder, \[α\]^24^~D~: −21.0° (c 0.6, MeOH). HRESIMS, *m/z*: 473.2369 (\[M+Na\]^+^; calcd for C~21~H~38~O~10~Na, 473.2363). IR (KBr) ν~max~: 3450 cm^−1^. ^1^H and ^13^C-NMR: See [Table 1](#molecules-17-07629-t001){ref-type="table"}.

Compound **2**: Colorless amorphous powder. HRESIMS, *m/z*: 471.2209 (\[M+Na\]^+^; calcd for C~21~H~36~O~10~Na, 471.2206). IR (KBr) ν~max~: 3440 cm^−1^. ^1^H-NMR (DMSO-d~6~) δ: 1.57 (s, 3H, H-9), 1.61 (s, 3H, H-10), 1.64 (s, 3H, H-8), 1.99 (2H, t, *J* = 6.8 Hz, H-4), 2.05 (2H, m, H-5), 4.08 (1H, dd, *J* = 11.9, 7.6 Hz, H-1a), 4.19(1H, dd, *J* = 11.9, 6.1 Hz, H-1b), 5.07 (1H, t-like, *J* = 6.8 Hz, H-6), 5.26 (1H, m, H-2); 4.11 (1H, d, *J* = 7.8 Hz, glc-H1), 2.95 (1H, t-like, *J* = 8.0 Hz, glc-H2), 3.12 (1H, t-like, *J* = 8.8 Hz, glc-H3), 2.98 (1H, t-like, *J* = 8.8 Hz, glc-H4), 3.25 (1H, t-like, *J* = 8.4 Hz, glc-H5), 3.86 (1H, d-like, *J* = 9.9 Hz, glc-H6a), 3.39 (1H, m, glc-H6b); 4.79 (1H, d, *J* = 1.6 Hz, ara-H1), 3.79 (1H, m, ara-H2), 3.62 (1H, m, ara-H3), 3.72 (1H, m, ara-H4), 3.52 (1H, d-like, *J* = 13.4Hz, ara-H5a),3.40 (m, 1H, ara-H5b). ^13^C-NMR (DMSO-d~6~) δ: 16.1(C-10), 17.6 (C-9), 25.6 (C-8), 25.9 (C-5), 39.4(C-4), 64.2 (C-1), 120.6 (C-2), 123.9 (C-6), 130.4 (C-7), 139.4 (C-3); 101.3 (glc-C1), 73.3 (glc-C2), 76.7 (glc-C3), 70.5 (glc-C4), 75.5 (glc-C5), 67.2 (glc-C6); 108.5 (ara(f)-C1), 82.1 (ara(f)-C2), 77.3 (ara(f)-C3), 83.8 (ara(f)-C4), 61.4 (ara(f)-C4).

Compound **3**: Colorless amorphous powder. HRESIMS, *m/z*: 471.2208 (\[M+Na\]^+^; calcd for C~21~H~36~O~10~Na, 471.2206). IR (KBr) ν~max~: 3445 cm^−1^. ^1^H-NMR (DMSO-d~6~) δ: 1.57 (s, 3H, H-9), 1.61 (s, 3H, H-10), 1.64 (s, 3H, H-8), 1.99 (2H, t, *J* = 6.8 Hz, H-4), 2.05 (2H, t, *J* = 6.8 Hz, H-5), 4.06 (1H, dd, *J* = 12.7, 7.3 Hz, H-1a), 4.22(1H, dd, *J* = 12.7, 6.0 Hz, H-1b), 5.08(1H, t-like, *J* = 6.5 Hz, H-6), 5.28 (1H, *J* = 6.5 Hz, H-2); 4.12 (1H, d, *J* = 7.8 Hz, glc-H1), 4.20 (1H, d, *J* = 6.0 Hz, ara-H1). ^13^C-NMR (DMSO-d~6~) δ: 16.1 (C-10), 17.6 (C-9), 25.5 (C-8), 25.8 (C-5), 39.3 (C-4), 64.4 (C-1), 120.7 (C-2), 123.9 (C-6), 130.9 (C-7), 139.1 (C-3); 101.5 (glc-C1), 73.3 (glc-C2), 76.6 (glc-C3), 70.5 (glc-C4), 75.6 (glc-C5), 67.2 (glc-C6); 103.4 (ara(p)-C1), 70.1 (ara(p)-C2), 72.5 (ara(p)-C3), 68.5(ara(p)-C4), 64.7 (ara(p)-C4).

Compound **4**: Colorless amorphous powder. HRESIMS, *m/z*: 789.4404 (\[M+Na\]^+^; calcd for C~41~H~66~O~13~Na, 789.4401). IR (KBr) ν~max~: 3440, 1720 cm^−1^. ^1^H-NMR (DMSO-d~6~) δ: 5.24 (1H, d, *J* = 7.8 Hz, glc-H1), 5.23(1H, br.s, H-12), 4.45 (1H, d, *J* = 7.0Hz, ara-H1), 3.11 (1H, br.s, H-19), 3.01 (1H, dd, *J* = 11.5, 3.9 Hz, H-3), 2.91(1H, br.s, H-18), 1.23 (3H, s, Me-27), 0.97 (3H, s, Me-23), 0.87 (3H × 2, s, Me-26 and Me-29), 0.85 (3H, s, Me-30), 0.76 (3H, s, Me-24), 0.65(3H, s, Me-25). ^13^C-NMR (DMSO-d~6~) δ: 38.0(C-1), 25.6 (C-2), 87.7 (C-3), 38.8 (C-4), 55.1 (C-5), 17.9 (C-6), 32.3 (C-7), 40.2 (C-8), 47.3 (C-9), 36.4 (C-10); 23.2 (C-11), 122.3 (C-12), 143.2 (C-13), 41.1 (C-14), 28.3 (C-15), 27.0 (C-16); 45.2 (C-17), 43.2 (C-18), 80.0 (C-19), 34.8 (C-20), 27.8 (C-21), 31.8 (C-22), 27.6 (C-23), 16.4 (C-24), 15.1 (C-25), 16.6 (C-26); 24.5 (C-27), 175.8 (C-28), 28.0 (C-29), 24.0 (C-30); 94.1 (glc-C1), 72.4 (glc-C2), 76.7 (glc-C3), 69.5 (glc-C4), 77.7 (glc-C5), 60.6 (glc-C6); 105.8 (ara(p)-C1), 71.0 (ara(p)-C2), 72.7 (ara(p)-C3), 67.6 (ara-C4), 65.1 (ara-C4).

Compound **5**: Colorless amorphous powder. HRESIMS, *m/z*: 789.4403 (\[M+Na\]^+^; calcd for C~41~H~66~O~13~Na, 789.4401). IR (KBr) ν~max~: 3475, 1740 cm^−1^. ^1^H-NMR (DMSO-d~6~) δ: 5.16 (1H, d, *J* = 7.8 Hz, glc-H1), 5.17(1H, br.s, H-12), 4.12 (1H, d, *J* = 6.0Hz, ara-H1), 3.11 (1H, br.s, H-19), 3.01 (1H, dd, *J* = 11.1, 3.9 Hz, H-3), 2.36(1H, br.s, H-18), 1.23 (3H, s, Me-27), 1.09 (3H, s, Me-29), 0.97 (3H, s, Me-23), 0.88 (3H, s, Me-26), 0.84(3H, d, *J* = 6.6 Hz, Me-30), 0.76 (3H, s, Me-25), 0.67 (3H, s, Me-24). ^13^C-NMR (DMSO-d~6~) δ: 38.2(C-1), 25.7 (C-2), 87.8 (C-3), 38.7 (C-4), 55.0 (C-5), 17.9 (C-6), 32.5 (C-7), 39.4 (C-8), 46.7 (C-9), 36.2 (C-10); 23.2 (C-11), 127.0 (C-12), 138.2 (C-13), 41.2 (C-14), 28.1 (C-15), 25.1 (C-16); 47.3 (C-17), 53.2 (C-18), 71.6 (C-19), 41.0 (C-20), 25.8 (C-21), 36.6 (C-22), 27.6 (C-23), 16.4 (C-24), 15.2 (C-25), 16.4 (C-26); 23.8 (C-27), 175.5 (C-28), 26.4 (C-29), 16.2 (C-30); 94.1 (glc-C1), 72.2 (glc-C2), 76.7 (glc-C3), 69.5 (glc-C4), 77.6 (glc-C5), 60.6 (glc-C6); 105.8 (ara(p)-C1), 71.0 (ara(p)-C2), 72.7 (ara(p)-C3), 67.6 (ara-C4), 65.1 (ara-C4).

Compound **6**: Colorless amorphous powder. HRESIMS, *m/z*: 657.39783 (\[M+Na\]^+^; calcd for C~36~H~58~O~9~Na, 657.39785). IR (KBr) ν~max~: 3440, 1720 cm^−1^. ^1^H-NMR (DMSO-d~6~) δ: 5.23 (1H, d, *J* = 7.6 Hz, glc-H1), 5.23(1H, br.s, H-12), 3.11 (1H, br.s, H-19), 3.00 (1H, dd, *J* = 11.2, 3.9 Hz, H-3), 2.91(1H, br.s, H-18), 1.23 (3H, s, Me-27), 0.89 (3H, s, Me-23), 0.87 (3H, s, Me-29), 0.84 (3H × 2, s, Me-25 and Me-30), 0.68 (3H, s, Me-24), 0.64(3H, s, Me-25). ^13^C-NMR (DMSO-d~6~) δ: 38.0 (C-1), 26.9 (C-2), 77.7 (C-3), 38.4 (C-4), 54.9 (C-5), 18.1 (C-6), 32.3 (C-7), 40.2 (C-8), 47.3 (C-9), 36.7 (C-10); 23.2 (C-11), 122.3 (C-12), 143.2 (C-13), 41.1 (C-14), 28.3 (C-15), 27.0 (C-16); 45.2 (C-17), 43.1 (C-18), 80.0 (C-19), 34.8 (C-20), 27.8 (C-21), 31.8 (C-22), 28.3 (C-23), 15.9 (C-24), 15.0 (C-25), 16.6 (C-26); 24.1 (C-27), 175.8 (C-28), 28.0 (C-29), 24.5 (C-30); 94.1 (glc-C1), 72.4 (glc-C2), 76.7 (glc-C3), 69.5 (glc-C4), 76.9 (glc-C5), 60.6 (glc-C6).

Compound **7**: Colorless amorphous powder. HRESIMS, *m/z*: 657.39784 (\[M+Na\]^+^; calcd for C~36~H~58~O~9~Na, 657.39785). IR (KBr) ν~max~: 3475, 1740 cm^−1^. ^1^H-NMR (DMSO-d~6~) δ: 5.16 (1H, d, *J* = 8.0 Hz, glc-H1), 5.17(1H, br.s, H-12), 4.12 (1H, d, *J* = 6.0Hz, ara-H1), 3.11 (1H, br.s, H-19), 3.00 (1H, dd, *J* = 11.0, 3.9 Hz, H-3), 2.37(1H, br.s, H-18), 1.27 (3H, s, Me-27), 1.08 (3H, s, Me-29), 0.89 (3H, s, Me-23), 0.85 (3H, s, Me-26), 0.84 (3H, d, *J* = 6.6 Hz, Me-30), (3H, s,), 0.67 (3H × 2, s, Me-25 and Me-24). ^13^C-NMR (DMSO-d~6~) δ: 38.2 (C-1), 27.0 (C-2), 77.6 (C-3), 38.4 (C-4), 54.8 (C-5), 18.1 (C-6), 32.6 (C-7), 39.2 (C-8), 46.7 (C-9), 36.5 (C-10); 23.2 (C-11), 127.0 (C-12), 138.1 (C-13), 41.2 (C-14), 28.1 (C-15), 25.1 (C-16); 47.3 (C-17), 53.2 (C-18), 71.6 (C-19), 41.1 (C-20), 25.4 (C-21), 36.6 (C-22), 28.2 (C-23), 16.4 (C-24), 15.1 (C-25), 16.2 (C-26); 23.8 (C-27), 175.5 (C-28), 26.4 (C-29), 16.0 (C-30); 94.0 (glc-C1), 72.2 (glc-C2), 76.7 (glc-C3), 69.5 (glc-C4), 76.9 (glc-C5), 60.6 (glc-C6).

3.3. Acid Hydrolysis of ***1--7***
----------------------------------

Solutions of **1**--**7** (each 1.0 mg) in 0.5 M H~2~SO~4~ (2.0 mL) were heated under reflux for 3 h. After cooling, each reaction mixture was diluted with H~2~O, neutralized with BaCO~3~, then filtered. The solution was partitioned with EtOAc to give two layers. The aqueous layer was evaporated and then subjected to TLC analysis with authentic sugar samples using *n*-BuOH--MeOH--CHCl~3~--HOAc (12.5:4.5:9:1.5:1, detection with aniline-phthalic acid). Compounds **1**--**5** afforded D-glucose (R~f~ = 0.30) and [L]{.smallcaps}-arabinose (R~f~ = 0.36), and **6**--**7** gave [D]{.smallcaps}-glucose (R~f~ = 0.30).

3.4. Bioactivity Assay
----------------------

The hemostasis assay was carried out by using a Goat Anti-Human α2-plasmin inhibitor kit which is a solid phase sandwich enzyme-linked quantitative immunoabsorbent assay (ELISA) with a purified antibody specific for α2-plasmin inhibitors. The above separated fractions and compounds were dissolved in dimethylsulfoxide (DMSO) (0.188 mg/μL for the fractions; 0.094 mg/μL for compounds), and were diluted with sample diluent (1:1). After an aliquot (50 μL) of the above samples or standards was added to each microplate well, a portion of biotinylated anti-α2-plasmin inhibitor (50 μL) was immediately added to each well, and the microplate was incubated for 1 h at 37 °C. After a wash with washing buffer, streptavidin-HRP was added, and the microplate was incubated for 30 min at 37 °C. Again, after a wash with washing buffer, substrate A and substrate B (50 μL each) were added to each well, and the microplate was incubated for 10 min at 37 °C. The enzyme-substrate reaction was stopped by quickly pipetting stopping solution (50 μL) into each well. The optical density absorbance (OD value) of each well was measured at 450 nm wavelength on a DG5033A enzyme immunoassay spectrophotometer. All the separated fractions and isolated compounds were tested for their hemostasis activities, and the results are summarized in [Table 2](#molecules-17-07629-t002){ref-type="table"}.

The correlation of calibration curve test data is shown in [Table 3](#molecules-17-07629-t003){ref-type="table"}. By using OD value as Y-axis(Y) and standards cocentration as X-axis (X), the linear regression equation, y = 0.0687x + 0.0317, r = 0.9997, was obtained. The results showed that the linear relation between OD value and concentration of standards were good and linearity domain of the measure is 0\~40g/L. Therefore the OD value is directly proportional the concentration of α2-plasmin inhibitor present in the samples.

molecules-17-07629-t003_Table 3

###### 

The correlation of calibration curve test data.

  Standards Concentration (g/L)   40       20       10      5.0      2.5      1.25     Control blank
  ------------------------------- -------- -------- ------- -------- -------- -------- ---------------
  OD                              2.9404   1.5171   0.828   0.4905   0.2955   0.0895   0.0214

Note: Y = 0.0687x + 0.0317, r = 0.9997, linearity domain: 0\~40 g/L; the OD value is directly proportional the concentration of α2-plasmin inhibitor present in the samples.

4. Conclusions
==============

Compound **1** is a new monoterpene glycoside and compounds **2**, **3** and **5** were isolated from the *Sanguisorba* genus for the first time. Compounds **1**--**7** were assayed for their hemostatic activities with a Goat Anti-Human α2-plasmin inhibitor ELISA kit, and the hemostatic constituent of *S. officinalis* wasidentified as ziyu-glycoside I (**5**). This is the first report that ziyu-glycoside I has strong hemostatic activity.
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